Tailored Drug Titration Using Artificial Intelligence
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
optima4BP
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Two or more blood pressure (BP) readings of ≥ 140/90 mmHg during UCSF primary care or cardiology office visits within the last 12 months
- Therapy with medications from at least 1 anti-HTN pharmacological agents at the time of the last office visit
- At least minimally "tech-savvy" defined as Ownership of a compatible smartphone and Ability to access the internet
- Active Electronic Health Record MyChart account
Exclusion Criteria:
- Home anti-HTN medication therapy doesn't match the electronic health record medication list
- Anti-HTN medication therapy changed within 30 days prior to enrollment
- Inability to operate a BP cuff
- Incompatible smartphone device (Galaxy S5 Android 5.0)
- Less than minimally "tech-savvy" defined as Inability to use the Internet
- Non-compliance with medical follow-up (>3 "no shows" in the previous 12 months)
- Planned coronary revascularization in the next 12 months
- Myocardial infarction, coronary revascularization, stroke, cardiac or aortic surgery in the previous 90 days
- GFR < 30 (CKD stage IV/ V)
- Treating physician rules out the patient due to superseding health management concerns
- Treating physician rules out the patient due to other concerns
Sites / Locations
- University of California San Francisco
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
optima4BP
Standard of Care (SOC)
Arm Description
Treating physicians receive periodic (every 5-8 weeks) medication treatment recommendations intended to optimize the current patient treatment. The recommendations are generated based on periodic remote data collected from the patient and from the Electronic Health Record. The analysis of the data allows assessment of the patient's response to current treatment and need for a treatment optimization. If a treatment optimization is needed, one is generated and sent to the treating physician for consideration.
The treating physician follows usual care practices.
Outcomes
Primary Outcome Measures
Reduction in systolic BP [SBP] (mmHg) measured remotely [Time frame: 0 - 6 months]
optima4BP leads ≥4mmHg of SBP reduction compared to Standard of Care
Secondary Outcome Measures
Incidence of Adverse Events [Time Frame: full 12 months]
Frequency and severity of adverse events (AEs) between baseline and the end of the study.
Sustained remote SBP Target during observational period [Time Frame: 6 - 12 months (end of study)]
Without optima4BP intervention, the O4BP arm will maintain a ≥4mmHg remote systolic blood pressure (SBP) reduction compared to the SOC arm
Full Information
NCT ID
NCT04223934
First Posted
January 8, 2020
Last Updated
June 27, 2023
Sponsor
Optima Integrated Health
Collaborators
University of California, San Francisco
1. Study Identification
Unique Protocol Identification Number
NCT04223934
Brief Title
Tailored Drug Titration Using Artificial Intelligence
Official Title
ARTERY Outcomes: Tailored Drug Titration Through Artificial Intelligence - an Interventional Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
February 18, 2020 (Actual)
Primary Completion Date
December 30, 2022 (Actual)
Study Completion Date
June 27, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Optima Integrated Health
Collaborators
University of California, San Francisco
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.
Detailed Description
Nearly 34 million Americans have their blood pressure (BP) uncontrolled. Hypertension (HTN) claims 1000 deaths every day. Despite medication and life-style management, the cost of HTN associated hospitalizations had escalated to $113 billion in 2016, or 15% of all hospital costs, with >135 million Emergency Department (ED) visits.
Uncontrolled HTN for even a few weeks is associated with increased risk for acute cardiovascular (CVD) events [stroke, heart failure (HF), myocardial infarction (MI)] and death. Medication treatment optimization to BP goal reduces the incidence of stroke by 35-40%, HF by up to 64%, and MI by 15-25%.
optima-for-blood pressure [optima4BP] transforms the episodic and reactive nature of uncontrolled HTN pharmacological treatment management into a process that is continuous, proactive, and personalized. The innovation simulates the established clinical reasoning treatment decision process undertaken during a patient's visit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, intervention versus control.
Masking
Participant
Masking Description
Patient blinded to assignment [intervention versus control].
Allocation
Randomized
Enrollment
164 (Actual)
8. Arms, Groups, and Interventions
Arm Title
optima4BP
Arm Type
Experimental
Arm Description
Treating physicians receive periodic (every 5-8 weeks) medication treatment recommendations intended to optimize the current patient treatment.
The recommendations are generated based on periodic remote data collected from the patient and from the Electronic Health Record. The analysis of the data allows assessment of the patient's response to current treatment and need for a treatment optimization. If a treatment optimization is needed, one is generated and sent to the treating physician for consideration.
Arm Title
Standard of Care (SOC)
Arm Type
No Intervention
Arm Description
The treating physician follows usual care practices.
Intervention Type
Other
Intervention Name(s)
optima4BP
Intervention Description
optima4BP establishes a "no gaps" computational framework in determining the most effective treatment change that can optimize a patient's HTN management towards BP Target. All possible drug combination options available through the 16 anti-HTN drug classes and subclasses are quantitatively evaluated in the context of 5 actions: add a drug, remove a drug, replace a drug, increase a drug dose, and decrease a drug dose. The pharmacological intervention efficacy ranking is computed and the highest ranked treatment recommendation is selected for consideration by the treating physician.
Primary Outcome Measure Information:
Title
Reduction in systolic BP [SBP] (mmHg) measured remotely [Time frame: 0 - 6 months]
Description
optima4BP leads ≥4mmHg of SBP reduction compared to Standard of Care
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Incidence of Adverse Events [Time Frame: full 12 months]
Description
Frequency and severity of adverse events (AEs) between baseline and the end of the study.
Time Frame
6 months and 12 months
Title
Sustained remote SBP Target during observational period [Time Frame: 6 - 12 months (end of study)]
Description
Without optima4BP intervention, the O4BP arm will maintain a ≥4mmHg remote systolic blood pressure (SBP) reduction compared to the SOC arm
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Two or more blood pressure (BP) readings of ≥ 140/90 mmHg during UCSF primary care or cardiology office visits within the last 12 months
Therapy with medications from at least 1 anti-HTN pharmacological agents at the time of the last office visit
At least minimally "tech-savvy" defined as Ownership of a compatible smartphone and Ability to access the internet
Active Electronic Health Record MyChart account
Exclusion Criteria:
Home anti-HTN medication therapy doesn't match the electronic health record medication list
Anti-HTN medication therapy changed within 30 days prior to enrollment
Inability to operate a BP cuff
Incompatible smartphone device (Galaxy S5 Android 5.0)
Less than minimally "tech-savvy" defined as Inability to use the Internet
Non-compliance with medical follow-up (>3 "no shows" in the previous 12 months)
Planned coronary revascularization in the next 12 months
Myocardial infarction, coronary revascularization, stroke, cardiac or aortic surgery in the previous 90 days
GFR < 30 (CKD stage IV/ V)
Treating physician rules out the patient due to superseding health management concerns
Treating physician rules out the patient due to other concerns
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gabriela Voskerician, PhD
Organizational Affiliation
Optima Integrated Health
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Liviu Klein, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
Individual patient data will not be made available to other researchers.
Learn more about this trial
Tailored Drug Titration Using Artificial Intelligence
We'll reach out to this number within 24 hrs